ViGenCell Inc. (308080.KQ)
- Previous Close
3,215.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 4,820.00 - Volume
0 - Avg. Volume
138,598 - Market Cap (intraday)
62.511B - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ViGenCell Inc. specializes in immune cell therapy. It develops ViTier, a T-cell therapy platform that uses antigen-specific killer T cells to target and remove cancer cells; ViRanger, a T-cell gene therapy platform that uses innate killer T cells to target and eliminate abnormal cells; and ViMedier, an immunosuppressive cell therapy platform that uses the differentiation and expansion of cord blood derived myeloid suppressor cells for universal use. The company was founded in 1995 and is based in Seoul, South Korea.
www.vigencell.comRecent News: 308080.KQ
View MorePerformance Overview: 308080.KQ
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 308080.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 308080.KQ
View MoreValuation Measures
Market Cap
62.51B
Enterprise Value
25.07B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
223.68
Price/Book (mrq)
1.08
Enterprise Value/Revenue
89.88
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.91%
Return on Equity (ttm)
-21.71%
Revenue (ttm)
278.95M
Net Income Avi to Common (ttm)
-14.06B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
45.18B
Total Debt/Equity (mrq)
13.35%
Levered Free Cash Flow (ttm)
-6.44B